Using a metastatic BC cell line overexpressing GM-CSF (SV-BR-1-GM), BriaCell Therapeutics demonstrated that these cell lines can present not only TAAs, but also MHC I/II molecules and directly act as APCs [114]. The gene discussed is CSF2; the disease is breast cancer.